taf1b  (Proteintech)

Journal: Oncology Letters

Article Title: Identification of a novel FOXO3‑associated prognostic model in hepatocellular carcinoma

doi: 10.3892/ol.2025.14976

Figure Lengend Snippet: Identification of the 5-gene signature. (A) Forest plot of univariate Cox regression analysis in The Cancer Genome Atlas dataset. Cox results for the top five and bottom five genes. (B) Least absolute shrinkage and selection operator regression analysis. (C) λ curves show the least absolute shrinkage and the best λ was selected based on the minimum criteria. (D) The protein-protein interaction network between FOXO3 and 294 genes. FOXO3, DDX55, RAB10, RAB7A, TAF1B and TAF3 are highlighted by red dots and the remaining genes are represented by green dots. The color of the edges was determined by the combined score obtained from STRING. FOXO3, Forkhead box O3; DDX55, DEAD-box helicase 55; RAB10, RAB10, member RAS oncogene family; RAB7A, RAB7A, member RAS oncogene family; TAF1B, TATA-box binding protein associated factor, RNA polymerase I subunit B; TAF3, TATA-box binding protein associated factor 3; SLC4A1AP, solute carrier family 4 member 1 adaptor protein; ZNF765, zinc finger protein 765; MORC3, MORC family CW-type zinc finger 3; WWC2, WW and C2 domain containing 2; UBE3A, ubiquitin protein ligase E3A; SECISBP2L, SECIS binding protein 2 like; FAN1, FANCD2 And FANCI associated nuclease 1.

Article Snippet: The following antibodies were used: β-actin (1:1,000; cat. no. ET1702-52; HUABIO), DDX55 (1:1,000; cat. no. ER63225; HUABIO), RAB10 (1:1,000; cat. no. 11808-1-AP; Proteintech Group, Inc.), RAB7A (1:1,500; cat. no. 55469-1-AP; Proteintech Group, Inc.), TAF1B (1:500; cat. no. 12818-1-AP; Proteintech Group, Inc.), FOXO3 (1:1,000; cat. no. A9270; ABclonal Biotech Co., Ltd.) and TAF3 (1:500; cat. no. 18901-1-AP; Proteintech Group, Inc.), HRP conjugated goat anti-rabbit IgG polyclonal antibody (1:30000, HA1001, HUABIO), HRP conjugated goat anti-mouse IgG polyclonal antibody (1:30,000, HA1006, HUABIO).

Techniques: Selection, Binding Assay, Ubiquitin Proteomics

Journal: Oncology Letters

Article Title: Identification of a novel FOXO3‑associated prognostic model in hepatocellular carcinoma

doi: 10.3892/ol.2025.14976

Figure Lengend Snippet: Construction and validation of a 5-gene prognostic model. (A) The distribution of RS, survival status and expression of the 5-gene signature between the high- and low-risk groups in TCGA dataset. (B) Overall survival of patients with HCC in the high- and low- RS groups in TCGA dataset. (C) Time-dependent ROC curve of RS in TCGA dataset. (D) The distribution of RS, survival status and expression of the 5-gene signature between the high- and low-risk groups in the ICGC dataset. (E) Overall survival of patients with HCC in the high- and low-RS groups in the ICGC dataset. (F) Time-dependent ROC curve of RS in the ICGC dataset. RS, risk score; TCGA, The Cancer Genome Atlas; ICGC, International Cancer Genome Consortium; ROC, receiver operating characteristic; DDX55, DEAD-box helicase 55; RAB10, RAB10, member RAS oncogene family; RAB7A, RAB7A, member RAS oncogene family; TAF1B, TATA-box binding protein associated factor, RNA polymerase I subunit B; TAF3, TATA-box binding protein associated factor 3; AUC, area under the curve.

Article Snippet: The following antibodies were used: β-actin (1:1,000; cat. no. ET1702-52; HUABIO), DDX55 (1:1,000; cat. no. ER63225; HUABIO), RAB10 (1:1,000; cat. no. 11808-1-AP; Proteintech Group, Inc.), RAB7A (1:1,500; cat. no. 55469-1-AP; Proteintech Group, Inc.), TAF1B (1:500; cat. no. 12818-1-AP; Proteintech Group, Inc.), FOXO3 (1:1,000; cat. no. A9270; ABclonal Biotech Co., Ltd.) and TAF3 (1:500; cat. no. 18901-1-AP; Proteintech Group, Inc.), HRP conjugated goat anti-rabbit IgG polyclonal antibody (1:30000, HA1001, HUABIO), HRP conjugated goat anti-mouse IgG polyclonal antibody (1:30,000, HA1006, HUABIO).

Techniques: Biomarker Discovery, Expressing, Binding Assay

Journal: Oncology Letters

Article Title: Identification of a novel FOXO3‑associated prognostic model in hepatocellular carcinoma

doi: 10.3892/ol.2025.14976

Figure Lengend Snippet: Identification of five biomarkers in HCC. (A) mRNA expression of DDX55, RAB10, RAB7A, TAF1B and TAF3 in HCC and normal tissues from TCGA. Overall survival curves in patients with HCC with high or low expression of (B) DDX55, (C) RAB10, (D) RAB7A, (E) TAF1B and (F) TAF3 from TCGA dataset. The best cut-off value for each gene was obtained using the X-tile software. (G) mRNA expression of DDX55, RAB10, RAB7A, TAF1B and TAF3 in HCC and paired paracancerous tissues from 10 patients with HCC, assessed using reverse transcription-quantitative PCR. (H) Immunohistochemical images of DDX55, RAB10 and RAB7A in HCC and normal tissues obtained from the HPA. (I) Protein expression of DDX55, RAB10, RAB7A, TAF1B and TAF3 in HCC and paired paracancerous tissues from 10 patients with HCC, evaluated using western blot analysis. The figure on the right is a relative semi-quantitative histogram of protein expression. The gray values were obtained by ImageJ and analyzed using GraphPad Prism. (J) Cell Counting Kit-8 curves after knockdown of RAB10, RAB7A and TAF3 in Huh7 cells by siRNA. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. T, tumor; NT, not-tumor; HCC, hepatocellular carcinoma; TCGA, The Cancer Genome Atlas; DDX55, DEAD-box helicase 55; RAB10, RAB10, member RAS oncogene family; RAB7A, RAB7A, member RAS oncogene family; TAF1B, TATA-box binding protein associated factor, RNA polymerase I subunit B; TAF3, TATA-box binding protein associated factor 3; HPA, The Human Protein Atlas; NC, negative control.

Article Snippet: The following antibodies were used: β-actin (1:1,000; cat. no. ET1702-52; HUABIO), DDX55 (1:1,000; cat. no. ER63225; HUABIO), RAB10 (1:1,000; cat. no. 11808-1-AP; Proteintech Group, Inc.), RAB7A (1:1,500; cat. no. 55469-1-AP; Proteintech Group, Inc.), TAF1B (1:500; cat. no. 12818-1-AP; Proteintech Group, Inc.), FOXO3 (1:1,000; cat. no. A9270; ABclonal Biotech Co., Ltd.) and TAF3 (1:500; cat. no. 18901-1-AP; Proteintech Group, Inc.), HRP conjugated goat anti-rabbit IgG polyclonal antibody (1:30000, HA1001, HUABIO), HRP conjugated goat anti-mouse IgG polyclonal antibody (1:30,000, HA1006, HUABIO).

Techniques: Expressing, Software, Reverse Transcription, Real-time Polymerase Chain Reaction, Immunohistochemical staining, Western Blot, Cell Counting, Knockdown, Binding Assay, Negative Control

Journal: Heliyon

Article Title: Inhibition of TAF1B impairs ribosome biosynthesis and suppresses cell proliferation in stomach adenocarcinoma through promoting c-MYC mRNA degradation

doi: 10.1016/j.heliyon.2023.e23167

Figure Lengend Snippet: TAF1B is overexpressed in STAD. (A) The mRNA expression of TAF1B was analyzed using the web-based tool GEPIA. T, tumor sample; N, normal tissue. *, P < 0.05. (B) Expression of TAF1B in gastric gland tissue of patients with gastric cancer. Scale bar represents 50 μm. CT: cancerous tissue; PCT: paracancerous tissue. (C) TAF1B was highly expressed in STAD cancer cell lines. GES-1 is a normal gastric epithelium cell line.

Article Snippet: Antibodies targeting TAF1B (PA5-112,957), TAF1D (PA5-25509), and RPL11 (#37–3000) were purchased from Thermo Fisher Scientific (Shanghai, China).

Techniques: Expressing

Journal: Heliyon

Article Title: Inhibition of TAF1B impairs ribosome biosynthesis and suppresses cell proliferation in stomach adenocarcinoma through promoting c-MYC mRNA degradation

doi: 10.1016/j.heliyon.2023.e23167

Figure Lengend Snippet: Depletion of TAF1B inhibits proliferation and survival of gastric cancer cells. SGC-7901 cells were stably transduced with lentiviruses containing expressing vectors of either control or TAF1B shRNAs (#2 and #6). The cell lysates were collected 3 days after transduction. (A) SGC-7901 cells were counted for 4 days after seeding. Upper left, Western blot analysis shows TAF1B knockdown efficiency. Lower left, cell growth curves of SGC-7901 cells. (B) The representative images of colony formation assays. Lower, colony numbers and diameters per field were calculated for at least 3 fields. (C) Rescue assay of TAF1B in SGC-7901 cells. Upper left, the examination of knockdown and re-expression of TAF1B in cells by western blotting. Cell growth curves were measured for 4 days. (D) The colonies were stained and photographed 14 days after seeding, the numbers and diameters per field were calculated for at least 3 fields. (E, F) The representative images of immunochemical staining with Ki67 (cell proliferation marker) and EdU (detect DNA synthesis) in SGC-7901 cells transduced with scramble or TAF1B shRNAs (#2 and #6), respectively. Scale bar represents 50 μm. Right, quantification of Ki67 and EdU positive cells (n = 3). (G) Cell cycle distribution after TAF1B knockdown. Data are shown as means ± SD (n = 3). *, P < 0.05; **, P < 0.01; NS, no significance.

Article Snippet: Antibodies targeting TAF1B (PA5-112,957), TAF1D (PA5-25509), and RPL11 (#37–3000) were purchased from Thermo Fisher Scientific (Shanghai, China).

Techniques: Stable Transfection, Transduction, Expressing, Control, Western Blot, Knockdown, Rescue Assay, Staining, Marker, DNA Synthesis

Journal: Heliyon

Article Title: Inhibition of TAF1B impairs ribosome biosynthesis and suppresses cell proliferation in stomach adenocarcinoma through promoting c-MYC mRNA degradation

doi: 10.1016/j.heliyon.2023.e23167

Figure Lengend Snippet: Deprivation of TAF1B inhibits STAD tumor growth in vivo . MKN-45 cells expressing doxycycline (Dox)–induced TAF1B shRNA were amplified by tissue culture. (A) The efficiency of knockdown after Dox induction was examined. (B) Nude mice implanted with MKN-45 cells received Dox to induce shRNA expression in the 3rd week after the tumor implantation. Tumor volumes (n = 5) were measured by calipers per five days for 20 days. (C) The measurement of weight of dissected tumors (n = 5). (D) The representative images of Ki67 and TAF1B immunochemical staining in the tumors. Scale bar represents 20 μm. Data are shown as means ± SD (n = 5). **, P < 0.01.

Article Snippet: Antibodies targeting TAF1B (PA5-112,957), TAF1D (PA5-25509), and RPL11 (#37–3000) were purchased from Thermo Fisher Scientific (Shanghai, China).

Techniques: In Vivo, Expressing, shRNA, Amplification, Knockdown, Tumor Implantation, Staining

Journal: Heliyon

Article Title: Inhibition of TAF1B impairs ribosome biosynthesis and suppresses cell proliferation in stomach adenocarcinoma through promoting c-MYC mRNA degradation

doi: 10.1016/j.heliyon.2023.e23167

Figure Lengend Snippet: Deficiency of TAF1B disrupts internal interaction of PIC complex and causes dissociation of Pol I from rDNA promotors. SGC-7901 cells were stably transduced with lentiviruses containing expressing vectors of either scramble or TAF1B shRNAs (#2 and #6). The cell lysates were collected 3 days after transduction. (A) The protein abundance of major components of PIC complex was examined by western blotting after TAF1B knockdown. (B) TAF1A specific antibody was used to immunoprecipitated endogenous TAF1A from SGC-7901 cells lysates with indicated treatment. The binding of TAF1C or TBP to TAF1A was examined by western blotting. (C) RRN3 specific antibody was used to immunoprecipitated endogenous RRN3 from SGC-7901 cells lysates with indicated treatment. The binding of Pol Iα to TAF1A was examined by western blotting. (D) The interaction of Pol Iα and Pol Iβ was immunoprecipitation assay. (E) The binding of RNA polymerase Iα and Iβ to rDNA was analyzed by ChIP-qPCR. The positions of amplification primers were denoted numerically. Data are shown as means ± SD (n = 3). *, P < 0.05; **, P < 0.01.

Article Snippet: Antibodies targeting TAF1B (PA5-112,957), TAF1D (PA5-25509), and RPL11 (#37–3000) were purchased from Thermo Fisher Scientific (Shanghai, China).

Techniques: Stable Transfection, Transduction, Expressing, Quantitative Proteomics, Western Blot, Knockdown, Immunoprecipitation, Binding Assay, ChIP-qPCR, Amplification

Journal: Heliyon

Article Title: Inhibition of TAF1B impairs ribosome biosynthesis and suppresses cell proliferation in stomach adenocarcinoma through promoting c-MYC mRNA degradation

doi: 10.1016/j.heliyon.2023.e23167

Figure Lengend Snippet: Knockdown of TAF1B represses rRNA synthesis and causes segregation of nucleolar proteins. SGC-7901 cells were stably transduced with lentiviruses containing expressing vectors of either control or TAF1B shRNAs (#2 and #6). The cell lysates were collected 3 days after transduction. (A) De novo rRNA synthesis in SGC-7901 cells was measured by EU labeling. Scale bar represents 50 μm. (B) The mRNA expression of pre-rRNA was determined by qRT-PCR (n = 3). Data are shown as means ± SD. *, P < 0.05; **, P < 0.01. (C) The representative images from the silver staining for argyrophilic nucleolar organizer region-associated proteins (AgNORs). Scale bar represents 5 μm. Right, quantitation of AgNORs area for at least 5 fields. (D) Knockdown of TAF1B induced redistribution of fibrillarin (FBL), nucleophosmin (NPM) and nucleolin (NCL). Scale bar represents 5 μm.

Article Snippet: Antibodies targeting TAF1B (PA5-112,957), TAF1D (PA5-25509), and RPL11 (#37–3000) were purchased from Thermo Fisher Scientific (Shanghai, China).

Techniques: Knockdown, Stable Transfection, Transduction, Expressing, Control, Labeling, Quantitative RT-PCR, Silver Staining, Quantitation Assay

Journal: Heliyon

Article Title: Inhibition of TAF1B impairs ribosome biosynthesis and suppresses cell proliferation in stomach adenocarcinoma through promoting c-MYC mRNA degradation

doi: 10.1016/j.heliyon.2023.e23167

Figure Lengend Snippet: Knockdown of TAF1B inactivates c-MYC. MKN-45 cells were stably transduced with lentiviruses containing expressing vectors of either control or TAF1B shRNAs. The cell lysates were collected 3 days after transduction. (A) The amount of p53 protein were examined by western blotting after TAF1B knockdown. (B) The expression of c-MYC mRNA was determined by qRT-PCR (n = 3). (C) The amount of c-MYC protein were examined by western blotting after TAF1B knockdown. (D) Knockdown of TAF1B -induced redistribution of RPL11 and nucleolin (NCL). Asterisks, cap structures. Scale bar represents 5 μm. (E) RPL5 specific antibody was used to immunoprecipitated endogenous RPL5 from MKN-45 cells lysates with indicated treatment. The binding of TRBP to RPL5 was examined by western blotting. (F) Relative enrichment of RPL5 with c-MYC mRNA was determined by RNA immunoprecipitation from MKN-45 cells lysates with indicated treatment. Ct values of each RIP reaction were normalized to input fractions to obtain ΔCt, and c-MYC fold-enrichment represent ΔΔCt values derived from normalized ΔCt values of RPL5 and IgG RIPs at each treatment (n = 3). Data are shown as means ± SD. *, P < 0.05; **, P < 0.01.

Article Snippet: Antibodies targeting TAF1B (PA5-112,957), TAF1D (PA5-25509), and RPL11 (#37–3000) were purchased from Thermo Fisher Scientific (Shanghai, China).

Techniques: Knockdown, Stable Transfection, Transduction, Expressing, Control, Western Blot, Quantitative RT-PCR, Immunoprecipitation, Binding Assay, RNA Immunoprecipitation, Derivative Assay